Dime Community Bancshares reported Q3 2026 earnings per share of $0.91, surpassing analyst estimates of $0.86, and revenue of $135.30 million, exceeding expectations. The company showed a 17.1% year-over-year revenue increase, highlighting robust financial performance. This marks consistent outperformance, with the bank beating earnings in three of the last four quarters and revenue in all four. The strong results reflect the bank's effective business model and position it well for future growth.
Dime Community Bancshares Q3 2026 earnings beat is the subject, with Pluang's Financials-sector market data providing context. Of 142 priced Financials-sector US stocks tradable on Pluang, 124 rose and 18 fell today. Notable movers include BMNR at USD 22.84 (+5.89%), LMND at USD 45.64 (+5.77%), and RKT at USD 11.28 (+5.28%). This snapshot is as of Oct 21, 2026 02:31 WIB.
Catholic Medical Mission Board (CMMB) held a ribbon-cutting ceremony for its new Distribution Center at the Brethren Service Center in New Windsor, Maryland. This move enhances CMMB's Access to Medicines Program by expanding operational capacity and ...
Piper Sandler upgraded Myriad Genetics from Underweight to Neutral and set a $5.00 price target after the company agreed to sell its prenatal health testing business to Labcorp for $210 million in cash. This sale includes several prenatal tests and i...
Brunello Cucinelli, an Italian luxury fashion company, raised its 2026 outlook following stronger-than-expected third-quarter sales. Citigroup maintains a Buy rating on the stock, which trades around $9.43 with a market cap of approximately $6.41 bil...
Annaly Capital Management is set to report its Q3 2026 earnings with expectations of $0.77-$0.78 EPS and $637 million revenue. Analysts highlight strong growth in net interest income and servicing income, but rising interest rates above 5% on the 10-...
H.C. Wainwright upgraded Rapport Therapeutics' price target from $40 to $66 following positive Phase 2 trial results of RAP-219 for acute bipolar mania. The drug met its primary endpoint, showing significant symptom improvement, and is moving toward ...
